Ibutilida

Ibutilida Uses, Dosage, Side Effects, Food Interaction and all others data.

Ibutilida is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).

Ibutilida prolongs the action potential duration and increases both atrial and ventricular refractoriness in vivo, i.e., class III electrophysiologic effects. Voltage clamp studies indicate that ibutilide, at nanomolar concentrations, delays repolarization by activation of a slow, inward current (predominantly sodium), rather than by blocking outward potassium currents, which is the mechanism by which most other class III antiarrhythmics act.

Table Of contents

• Ibutilida
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Ibutilida
Availability	Prescription only
Generic	Ibutilide
Ibutilide Other Names	Ibutilid, Ibutilida, Ibutilide, Ibutilidum
Related Drugs	propranolol, Xarelto, diltiazem, digoxin, rivaroxaban, sotalol, flecainide, propafenone, Multaq, esmolol
Type
Formula	C20H36N2O3S
Weight	Average: 384.576 Monoisotopic: 384.244663718
Protein binding	40%
Groups	Approved
Therapeutic Class
Manufacturer
Available Country
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ibutilida is a class III antiarrhythmic agent used to correct atrial fibrillation and atrial flutter, which can be considered as an alternative to cardioversion.

Indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm.

Ibutilida is also used to associated treatment for these conditions: Atrial Fibrillation, Flutter, Atrial

How Ibutilida works

Ibutilida is a 'pure' class III antiarrhythmic drug, used intravenously against atrial flutter and fibrillation. At a cellular level it exerts two main actions: induction of a persistent Na+ current sensitive to dihydropyridine Ca²⁺ channel blockers and potent inhibition of the cardiac rapid delayed rectifier K⁺ current, by binding within potassium channel pores. In other words, Ibutilida binds to and alters the activity of hERG potassium channels, delayed inward rectifier potassium (IKr) channels and L-type (dihydropyridine sensitive) calcium channels

Toxicity

Acute overdose in animals results in CNS toxicity; notably, CNS depression, rapid gasping breathing, and convulsions. The intravenous median lethal dose in the rat was more than 50 mg/kg which is, on a mg/m² basis, at least 250 times the maximum recommended human dose.

Food Interaction

No interactions found.

Ibutilida Drug Interaction

Unknown: ramipril, ramipril, trolamine salicylate topical, trolamine salicylate topical, lorazepam, lorazepam, ipratropium, ipratropium, amoxicillin / clavulanate, amoxicillin / clavulanate, dutasteride, dutasteride, insulin glargine, insulin glargine, acetaminophen, acetaminophen, metoclopramide, metoclopramide, rivaroxaban, rivaroxaban

Ibutilida Disease Interaction

Major: cardiovascular dysfunction, proarrhythmic effectsModerate: electrolyte imbalance, hepatic/renal

Volume of Distribution

• 11 L/kg

Elimination Route

Rapid after intravenous injection

Half Life

6 hours (ranges from 2-12 hours)

Clearance

• 29 mL/min/kg

Elimination Route

In healthy male volunteers, about 82% of a 0.01 mg/kg dose of [14C] ibutilide fumarate was excreted in the urine (about 7% of the dose as unchanged ibutilide) and the remainder (about 19%) was recovered in the feces.

Innovators Monograph

You find simplified version here Ibutilida